| Project/Area Number |
21390073
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | Dokkyo Medical University (2011)
Kyorin University (2009-2010) |
|---|
Principal Investigator |
ANZAI Naohiko 獨協医科大学, 医学部, 教授 (70276054)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UCHIDA Kohsuke 獨協医科大学, 医学部, 准教授 (30168695)
KOJIMA Shuichi 獨協医科大学, 医学部, 准教授 (60178267)
DOMAE Mariko 獨協医科大学, 医学部, 助教 (20285878)
HAYASHI Keitaro 獨協医科大学, 医学部, 助教 (10323106)
YAN Kunimasa 杏林大学, 医学部, 教授 (70255389)
KIMURA Toru 杏林大学, 医学部, 助教 (30433725)
FUKUTOMI Toshiyuki 杏林大学, 医学部, 助教 (30439187)
MIURA Daisaku 兵庫医療大学, 薬学部, 助教 (60510873)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
KANAI Yoshikatsu 大阪大学, 大学院・医学系研究科, 教授 (60204533)
KAWAHARA Katsumasa 北里大学, 医学部, 教授 (70134525)
|
|---|
| Research Collaborator |
WEMPE Michael F. 米国Colorado, 大学薬理学, 教授
ENDOU Hitoshi ジェイファーマ株式会社, 代表取締役
TSUKADA Ai 東京薬科大学, 大学院・薬学研究科, 大学院生
AMMONPATUMRAT Sirirat 杏林大学, 医学部, 博士研究員
THAMMAPRATIP Thanapol 杏林大学, 医学部, 研究生
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥8,320,000 (Direct Cost: ¥6,400,000、Indirect Cost: ¥1,920,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2010: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2009: ¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
|
|---|
| Keywords | トランスポーター / 尿酸 / 痛風 / 高尿酸血症 / 腎尿細管 / 薬理学 / 遺伝子 / 蛋白質 |
|---|
| Research Abstract |
The purpose of this study was to clarify the mechanism for the onset of hyperuricemia and to develop a novel uricosuric drug targeting renal urate transporters by analyzing transgenic mice of urate efflux transporter URATv1 that expresses at the basolateral side of renal proximal tubules and the selection of candidate compounds that inhibit urate transport using URATv1 expression system. As a consequence, I could demonstrate experimentally that URATv1, functions as a basolateral urate exit, contributes to the reduced urinary urate excretion and found the important structure for raising novel uricosuric drug targeting URAT1.
|
